TABLE 3.
Study identifier | Strain first isolated | Strain last isolated | Multilocus ST | Strain duration (days)a | Rx no.b | Azithromycin MIC (μg/ml) |
|
---|---|---|---|---|---|---|---|
Initial | Final | ||||||
5 | 5P28H1 | 5P54H1c | 103 | 819 | 4 | 2 | 16 |
13 | 13P24H2 | 13P36H1 | 57 | 355 | 1 | 2 | 2 |
19 | 19P49H1 | 19P94H1 | 243 | 1,422 | 5 | 1 | 2 |
24 | 24P44H4 | 24P45H1c | 680 | 17 | 1 | 0.5 | 4 |
33 | 33P110H3 | 33P125H1 | 136 | 329 | 1 | 4 | 4 |
45 | 45P9H2 | 45P11H1 | 3 | 29 | 1 | 1 | 2 |
48 | 48P106H1 | 48P153H1 | 155 | 993 | 2 | 1 | 2 |
48 | 48P160H1 | 48P162H1 | 196 | 28 | 1 | 1 | 1 |
49 | 49P5H1 | 49P21H1 | 85 | 672 | 1 | 1 | 1 |
56 | 56P1H1 | 56P16H1 | 265 | 469 | 1 | 2 | 1 |
67 | 67P38H1 | 67P56H1c | 156 | 570 | 2 | 1 | 4 |
67 | 67P10H5 | 67P50H1 | 411 | 1,380 | 1 | 1 | 1 |
73 | 73P2H1 | 73P39H1 | 14 | 1,175 | 1 | 4 | 4 |
84 | 84P18H1 | 84P20H1 | 66 | 77 | 1 | 4 | 4 |
87 | 87P128H2 | 87P138H1 | 389 | 140 | 2 | 4 | 4 |
91 | 91P109H1 | 91P114H1 | 98 | 70 | 1 | 1 | 0.5 |
91 | 91P3H3 | 91P4H1c | 411 | 29 | 1 | 1 | 4 |
94 | 94P17H1 | 94P20H1 | 139 | 98 | 1 | 0.5 | 2 |
99 | 99P41H1 | 99P50H1 | 3 | 212 | 1 | 1 | 1 |
101 | 101P3H1 | 101P19H1 | 12 | 474 | 2 | 2 | 4 |
102 | 102P20H1 | 102P32H1c | 159 | 364 | 1 | 0.5 | 4 |
103 | 103P3H1 | 103P20H1 | 155 | 565 | 2 | 1 | 0.5 |
107 | 107P50H1 | 107P75H1 | 215 | 560 | 7 | 2 | 4 |
122 | 122P4H1 | 122P13H1 | 11 | 254 | 1 | 2 | 4 |
126 | 126P11H1 | 126P26H1 | 66 | 344 | 1 | 0.5 | 2 |
128 | 128P1H1 | 128P56H1 | 98 | 932 | 3 | 2 | 4 |
138 | 138P2H1 | 138P39H1 | 203 | 721 | 1 | 1 | 2 |
Strain duration is defined as the number of days between the first date that the strain was identified and the last date that the strain was identified.
Rx no., number of courses of macrolides administered while the strain was carried.
MIC of azithromycin increased 4-fold or more and reached or exceeded the CLSI breakpoint (≤4 μg/ml) during carriage.